Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders Read more about Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders
Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit Read more about Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit
Galectin Therapeutics Reports Q3 2019 Financial Results Read more about Galectin Therapeutics Reports Q3 2019 Financial Results
Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis Read more about Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis
Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting Read more about Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy Read more about Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update Read more about Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA Read more about Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise Read more about Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering Read more about Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering